Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Britain Secures Relationship With J&J & Novavax For Potential COVID-19 Vaccine Supplies

By John F. Heerdink, Jr.

As per reports, Britain has secured a deal for the potential COVID-19 vaccines from Johnson & Johnson (JNJ) and Novavax Inc. The latest addition brings Britain’s total number of doses to 340 million, with options for millions more for its population of 66 million.

“For now that is probably the bedrock of the portfolio. We basically need to see now, what we want to add, if anything, immediately that could diversify the sorts of vaccine that we’ve got in the hopper now,” stated Kate Bingham, chair of UK Vaccine Taskforce, told Reuters. “I think we’re well placed… but I think we need to see the data of some of these early vaccines first before we know what is likely to be protective and what is not.”

Johnson & Johnson’s Janssen Pharmaceutica unit is scheduled to supply Britain with its Ad26.COV2 vaccine, with an early sale of 30 million doses on a not-for-profit basis and emergency pandemic use with an option for additional purchase of up to 22 million doses. Additionally, Novavax to supply 60 million doses of its vaccine candidate, NVX-CoV2373 to Britain.

British government to work with J&J on a global Phase III trial to explore the two-dose regimen of its COVID-19 vaccine, along with Phase III single-dose trials and with Novavax on a late-stage British-based trial.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

Post View Count : 492
(Read Original Story: Britain lines up more potential COVID-19 vaccine supplies with J&J, Novavax deals in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us